SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine

Transplantation

Volumn 64, Issue 1, 1997, Pages 32-35

  Schuurman, Henk Jan ^a   Cottens, Sylvain ^a   Fuchs, Serge ^a   Joergensen, Joanne ^a   Meerloo, Timo ^a   Sedrani, Richard ^a   Tanner, Madeleine ^a   Zenke, Gerhard ^a   Schuler, Walter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; RAPAMYCIN; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; IMMUNOSUPPRESSIVE TREATMENT; MIXED LYMPHOCYTE REACTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ANIMALS; CYCLOSPORINE; DRUG SYNERGISM; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; POLYENES; RATS; SIROLIMUS;

EID: 0030814696     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00007     Document Type: Article

References (16)

1. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483.
2. Boyle MJ, Kahan BD. Immunosuppressive role of rapamycin in allograft rejection. In: Thomson AW, Starzl TE, eds. Immunosuppressive drugs: developments in anti-rejection therapy. London: Edward Arnold, 1994: 129.
3. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995; 27: 183.
4. Kahan BD, Murgia MG, Slaton J, Napoli K. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit 1995; 17: 672.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64(1): 36.
6. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou TC. Synergistic interactions of CsA and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes. Transplantation 1991; 72: 544.
7. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fisher PA, Sigal NH. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
8. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991; 23: 521.
9. Tu Y, Stepkowski SM, Chou TC, Kahan BD. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177.
10. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922.
11. Davies CB, Madden RL, Alexander JW, Cofer BR, Fisher RA, Anderson P. Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival. Transplantation 1993; 55: 1107.
12. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39.
13. Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation 1993; 56: 1293.
14. Knight R, Ferraresso M, Serino F, et al. Low-dose rapamycin potentiates the effects of subtherapeutic cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55: 947.
15. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression. Clin Exp Immunol 1977; 28: 1.
16. Chou TC, Stepkowski SM, Kahan BD. Computerized quantitation of immunosuppressive synergy for clinical protocol design. Transplant Proc 1994; 26: 3043.